C-Myc overexpression is one of the most common aberrations in human cancers. Here, the authors identified miR-33b as a negative regulator of c-Myc and show that lovastatin upregulates its expression resulting in suppressed c-Myc expression accompanied by reduced tumor growth and increased survival in mice.
Apana A. L. Takwi, Yan Li, Lindsey E. Becker Buscaglia, Jingwen Zhang, Saibyasachi Choudhury, Ae Kyung Park, Mofang Liu, Ken H. Young, Woong-Yang Park, Robert C. G. Martin and Yong Li
EMBO Mol Med 2012, 4(9), 896–909
Hypercholesterolemia patients are usually prescribed statins, which induces miR-33 and regulates HDL cholesterol in the liver. Baldan and colleagues show here that miR-33 also modulates expression of hepatic sterol transporters and thus contributes to the hepatotoxic effects of statins in patients.
Ryan M. Allen, Tyler J. Marquart, Carolyn J. Albert, Frederick J. Suchy, David Q.-H. Wang, Meenakshisundaram Ananthanarayanan, David A. Ford and Ángel Baldán
EMBO Mol Med 2012, 4(9), 882–895
Cardiac hypertrophy accompanies the majority of disease- and age-related cardiac pathologies. Here, the authors report that miR-142, which targets mediators of growth and survival, ensures that these signals remain quiescent in the non-stressed heart.
Salil Sharma, Jing Liu, Jianqin Wei, Huijun Yuan, Taifang Zhang and Nanette H. Bishopric
EMBO Mol Med 2012, 4(7), 617–632
This Review discusses the current knowledge about miRNAs therapeutics in cardiovascular diseases on their way to clinical use.
EMBO Mol Med 2012, 4(1), 3–14
Systemic lupus erythematosus (SLE) is a potentially fatal systemic autoimmune disease. The authors show that pharmacological in vivo inhibition of miR-21 using seed-targeting LNAs can alter the course of the disease in mice.
Barry G. Garchow, Oscar Bartulos Encinas, Yiu Tak Leung, Patricia Y. Tsao, Robert A. Eisenberg, Roberto Caricchio, Susanna Obad, Andreas Petri, Sakari Kauppinen and Marianthi Kiriakidou
EMBO Mol Med 2011, 3(10), 605–615
The authors report a blood test for the diagnosis of NSCLC of potential impact in the design of screening programmes for early detection in at-risk individuals, with perspective improvement in the prognosis of the disease.
Fabrizio Bianchi, Francesco Nicassio, Matteo Marzi, Elena Belloni, Valentina Dall'Olio, Loris Bernard, Giuseppe Pelosi, Patrick Maisonneuve, Giulia Veronesi and Pier Paolo Di Fiore
EMBO Mol Med 2011, 3(8), 495–503
Pei-Ying Lin and Pan-Chyr Yang
EMBO Mol Med 2011, 3(8), 436–437
Germ-line mutations in the BRCA1 gene strongly predispose women to breast cancer and the BRCA1 protein is absent or present at very low levels in about one third of sporadic breast cancers. This study reports the identification of two microRNAs negatively regulating BRCA1 expression.
Amandine I. Garcia, Monique Buisson, Pascale Bertrand, Ruth Rimokh, Etienne Rouleau, Bernard S. Lopez, Rosette Lidereau, Ivan Mikaélian and Sylvie Mazoyer
EMBO Mol Med 2011, 3(5), 279–290
The authors suggest that miR-1, miR-133, and miR-206 represent valuable biomarkers not only for the diagnosis of DMD onset and progression but also for monitoring the outcomes of therapeutic interventions in humans.
Davide Cacchiarelli, Ivano Legnini, Julie Martone, Valentina Cazzella, Adele D'Amico, Enrico Bertini and Irene Bozzoni
EMBO Mol Med 2011, 3(5), 258–265
Endometriosis is a common, benign gynecological disorder, which is a frequent cause of chronic pelvic pain and infertility in 5–15% of reproductive age women. This study identified a novel gene mutation, which is associated with up to one third of endometriosis cases.
Olga Grechukhina, Rafaella Petracco, Shota Popkhadze, Efi Massasa, Trupti Paranjape, Elcie Chan, Idhaliz Flores, Joanne B. Weidhaas and Hugh S. Taylor
EMBO Mol Med 2011, 3(3), 206–217
This Review focuses on the current status of RNAi-based therapeutics, the challenges it faces and how to overcome them.
Katrin Tiemann and John J. Rossi
EMBO Mol Med 2009, 1(3), 142–151